Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Institut Paoli Calmette Dpt of Oncology/Hematology, Marseille

Gachon University Gil Medical Center, Incheon

UVA Health System, Division of Hematology & Oncology, Charlottesville

Northside Hospital, Atlanta

Institut Universitaire du Cancer Toulouse Oncopole, Toulouse

Mayo Clinic, Jacksonville

Institut Bergonie - Centre Regional de Lutte Contre Le Cancer de Bordeaux et Sud Ouest, Bordeaux

CHU Haut-Leveque, Service d'Hematologie Clinique et Therapie Cellulaire, Pessac

Chu Montpellier, Hematologie Clinique St. Eloi, Montpellier

The Ohio State University Wexner Medical Center and James Cancer Hospital, Columbus

CHU de Nantes, Nantes

University of Michigan, Ann Arbor

Froedtert Hospital and Medical College of Wisconsin, Milwaukee

The University of Chicago Medicine, Chicago

Centre Hospitalier Lyon-Sud, Service d'Hematologie, Pierre-Bénite

Centre Henri Becquerel, Rouen

MD Anderson Cancer Center, Houston

Moores UC San Diego Cancer Center, La Jolla

Hopital Henri Mondor, Créteil

CLCC Institut Gustave Roussy, Villejuif

Swedish Cancer Institute, Seattle

Centre Antoine Lacassagne, Nice

Royal Marsden Hospital (RMH) - Royal Marsden NHS Foundation Trust, London